Tag Archives: BIO CEO

Where’s the Deal?

2011-drug-deals-thumb

With only two weeks to go in 2011 it is looking like a five year low for deals. The chart below shows therapeutic deals dropping every year since 2007. We use the Windhover/Elsevier Strategic Transaction Database as our starting point for deal analytics. We analyze each deal to determine if the deal is for a drug asset, removing generic/OTC deals, manufacturing/service deals, device/diagnostics/tools deals, and tech transfer deals. What remains are deals for biotech company Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO CEO Company Snapshot: NuPathe Inc.

NuPathe

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February.  The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. For our first Snapshot for the BIO CEO event, we’ve spoken with NuPathe Inc. about their Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Biotechnology – Creating a positive political and social environment

Tony Blair at 2011 BIO International Convention

“I think it’s important that government stands up for proper science,” Former British Prime Minister Tony Blair said during the Tuesday keynote luncheon at the 2001 BIO International Convention. “You know I had a lot of battles over this when I was prime minister – with various groups.” This was a familiar story to many of the attendees who regularly face a number of social and political hurdles in bringing their innovative products to market: Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , ,

2011, The Year of Positive Thinking? BIO/IPREO Study Reveals High Hopes for the Industry

BIO CEO’s closing plenary session featured plenty of crystal ball gazing and candid quips about what 2011 has in store for the biotech industry.  While the panel provided an in-depth look at how buy-side and sell-side analysts evaluate the industry, the BIO/IPREO Investor Perception Study reveals that the majority of investors believe biotech is headed in the right direction.  Access full study deck here: BIO CEO – IPREO Biotech Investor Perception Study The study also reveals that Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,